passiv
immun
monoclon
antibodi
rsv
palivizumab
help
reduc
influenza
rsv
infect
morbid
still
leav
uncov
acut
respiratori
viru
infect
burden
moreov
demonstr
influenza
vaccin
efficaci
lower
desir
young
infant
palivizumab
costeffect
mostli
highrisk
popul
antivir
use
influenza
treatment
neuraminidas
inhibitor
shorten
durat
symptom
help
reduc
relat
complic
efficaci
link
time
drug
prescript
young
children
underli
diseas
risk
factor
emphasi
histori
prematur
birth
congenit
heart
lung
diseas
greater
risk
unfavor
outcom
infect
respiratori
viru
therefor
avail
prevent
treatment
drug
direct
special
popul
although
major
strategi
high
cost
limit
efficaci
activ
viru
surveil
allow
good
season
plan
access
viru
detect
tool
etiolog
definit
respiratori
syndrom
lead
ration
usag
strategi
describ
clinic
laboratori
find
prospect
surveil
hospit
due
acut
respiratori
infect
young
children
tertiari
hospit
paulo
brazil
compar
outcom
infant
underli
diseas
previous
healthi
start
prospect
surveil
system
acut
respiratori
infect
ari
children
two
year
age
univers
hospit
paulo
citi
brazil
analysi
includ
clinic
epidemiolog
laboratori
data
collect
twoyear
time
period
march
februari
surveil
conduct
pediatr
depart
santa
casa
de
rdia
hospit
tertiari
care
center
receiv
patient
refer
center
serv
primari
hospit
surround
commun
enrol
sampl
collect
perform
monday
friday
pm
children
two
yearsold
elig
enrol
admit
hospit
acut
respiratori
symptom
cough
andor
difficult
breath
admit
diagnosi
bronchiol
pneumonia
wheez
croup
pertussi
paroxysm
cough
apnea
cyanosi
ill
consid
associ
specif
pathogen
detect
polymeras
chain
reaction
assay
pcr
describ
unit
analysi
hospit
individu
may
enrol
surveil
period
inform
regard
symptom
histori
underli
health
condit
immun
statu
collect
parent
guardian
interview
medic
record
antibiot
use
length
hospit
stay
oxygen
use
need
intens
care
mechan
ventil
data
retriev
medic
record
obtain
consent
enrol
specimen
collect
parentsguardian
singl
nasopharyng
aspir
npa
obtain
hospit
respiratori
technician
npa
kept
refriger
within
one
five
hour
divid
three
cryotub
per
sampl
store
liquid
nitrogen
weekli
specimen
sent
virolog
laboratori
univers
paulo
detect
respiratori
virus
pcr
sampl
test
follow
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
parainfluenza
viru
influenza
viru
b
ia
ib
adenoviru
adv
pandem
influenza
test
sampl
obtain
month
januari
februari
pcr
revers
transcript
rt
pcr
assay
develop
use
gene
scan
analysi
primer
previous
describ
iap
detect
real
time
pcr
assay
develop
center
diseas
control
prevent
cdc
rtqpcr
swine
flu
panel
protocol
specifi
sampl
collect
within
h
admiss
order
clinician
result
blood
cultur
also
record
vaccin
brazil
public
access
citizen
privat
clinic
permit
provid
vaccin
prophylaxi
includ
nation
immun
program
nip
brazilian
nip
provid
influenza
vaccin
children
month
year
age
age
group
underli
condit
risk
factor
recent
feder
recommend
rsv
prophylaxi
nevertheless
state
includ
paulo
studi
carri
specif
recommend
regard
rsv
prophylaxi
provid
free
charg
palivizumab
dose
season
infant
born
prematur
month
week
gestat
age
wga
children
year
age
chronic
lung
diseas
sever
congenit
heart
diseas
sinc
brazilian
pediatr
societi
recommend
univers
influenza
vaccin
children
older
month
extend
rsv
prophylaxi
prematur
infant
born
week
day
infant
neuromuscular
diseas
sever
immunosuppress
congenit
abnorm
airway
palivizumab
also
consid
dose
regimen
prematur
infant
born
gestat
age
week
week
day
least
one
risk
factor
born
month
rsv
season
studi
approv
research
ethic
committe
santa
casa
de
rdia
hospit
univers
paulo
written
inform
consent
obtain
parent
guardian
child
enrol
studi
data
analysi
limit
enrol
children
respiratori
specimen
collect
accord
studi
protocol
criteria
categor
variabl
compar
use
x
test
fischer
exact
test
appropri
student
test
mannwhitney
test
oneway
anova
use
continu
variabl
odd
ratio
determin
associ
underli
condit
hospit
specif
respiratori
viru
multivari
logist
regress
model
perform
take
account
known
risk
factor
sever
diseas
need
intens
care
age
hospit
day
normal
distribut
mannwhitney
u
test
use
compar
age
hospit
day
group
healthi
versu
underli
diseas
analys
perform
spss
softwar
version
statist
signific
consid
p
surveil
period
hospit
patient
met
elig
criteria
elig
npa
obtain
specimen
obtain
hour
admiss
specimen
exclud
due
inadequ
sampl
collect
therefor
includ
specimen
elig
patient
ad
total
individu
respiratori
virus
identifi
specimen
rsv
commonli
identifi
viru
posit
specimen
follow
adenoviru
hmpv
ia
ib
one
viru
identifi
specimen
mark
season
pattern
could
observ
rsv
hmpv
infect
figur
overal
children
hospit
month
six
month
younger
boy
predomin
popul
almost
half
case
children
underli
health
condit
includ
limit
histori
prematur
birth
congenit
heart
diseas
chronic
lung
diseas
syndrom
young
infant
less
like
underli
health
condit
older
month
inform
regard
use
influenza
vaccin
andor
palivizumab
rsv
prophylaxi
avail
children
includ
identifi
patient
met
elig
criteria
rsv
prophylaxi
consid
recommend
brazilian
pediatr
societi
nine
patient
receiv
palivizumab
previous
vaccin
influenza
hospit
includ
intens
care
requir
mechan
ventil
children
admit
intens
care
unit
icu
respiratori
viru
detect
rsv
commonli
detect
among
group
follow
adv
piv
frequent
clinic
diagnosi
bronchiol
attribut
hospit
admiss
among
respiratori
viru
detect
rsv
frequent
detect
one
viru
occur
case
mean
age
patient
bronchiol
month
histori
underli
health
condit
group
requir
intens
care
compar
healthi
children
risk
factor
underli
diseas
demonstr
children
least
one
underli
condit
significantli
older
stay
longer
hospit
like
admit
icu
like
requir
mechan
ventil
less
viru
coinfect
tabl
young
age
underli
diseas
independ
risk
factor
hospit
sever
diseas
multivari
analysi
logist
regress
demonstr
although
young
age
risk
factor
admiss
intens
care
unit
underli
condit
risk
increas
time
look
singleviru
detect
greater
proport
hospit
due
hmpv
piv
infect
children
underli
health
condit
compar
other
respect
opposit
observ
rsvrelat
hospit
major
patient
previous
healthi
p
tabl
differ
also
observ
frequenc
antibiot
prescript
children
admit
adenoviru
p
influenza
viru
receiv
antibiot
singleviru
detect
descript
analysi
reveal
posit
associ
detect
adenoviru
need
intens
care
adv
posit
vs
adv
neg
observ
influenza
viru
flu
posit
vs
flu
neg
analyz
infant
diagnosi
bronchiol
singleviru
detect
group
compar
situat
rsv
twelv
children
syndrom
ds
congenit
heart
diseas
present
patient
three
patient
histori
prematur
birth
two
children
need
mechan
ventil
demand
intens
care
half
patient
respiratori
viru
detect
hmpv
ia
adv
ia
adv
coinfect
one
child
die
cyanot
congenit
heart
diseas
admit
nonalveolar
pneumonia
blood
cultur
neg
hmpv
detect
npa
death
occur
nine
children
six
nine
infant
die
respiratori
viru
detect
distribut
follow
piv
hmpv
rsv
adv
one
coinfect
advrsv
six
underli
condit
requir
intens
care
mechan
ventil
studi
evalu
acut
respiratori
tract
infect
lead
hospit
young
children
larg
urban
center
brazil
found
larg
proport
underli
condit
compar
previous
healthi
group
comorbid
sever
outcom
prolong
hospit
stay
need
intens
care
special
popul
also
behav
differ
manner
usual
describ
healthi
children
virus
associ
mild
symptom
respons
acut
respiratori
failur
death
demonstr
human
metapneumoviru
parainfluenza
virus
usual
associ
less
sever
diseas
sinc
discoveri
human
metapneumoviru
relat
acut
respiratori
tract
infect
infant
worldwid
heikkinen
et
al
studi
children
year
old
acut
respiratori
infect
demonstr
higher
incid
rate
children
less
month
cohort
previous
healthi
children
infect
hmpv
mild
moder
symptom
need
hospit
wherea
highrisk
popul
greater
chanc
poor
outcom
virus
usual
associ
mild
diseas
ex
hmpv
possibl
respiratori
virus
rsv
adv
inde
caus
sever
infect
irrespect
health
condit
statu
marguet
et
al
studi
evalu
role
respiratori
viru
sever
bronchiol
show
young
infant
median
age
month
previous
healthi
sever
present
rsv
caus
diseas
compar
respiratori
virus
hand
hmpv
caus
bronchiol
lower
risk
prolong
hospit
stay
observ
signific
clinic
demograph
differ
among
differ
etiolog
infant
diagnosi
bronchiol
rsv
caus
agent
patient
fewer
comorbid
tendenc
younger
patient
virus
garcia
et
al
public
risk
factor
children
hospit
due
bronchiol
compar
rsv
versu
nonrsv
case
report
similar
result
underli
diseas
group
without
rsv
vs
rsv
posit
detect
rate
respiratori
virus
studi
similar
studi
use
compar
diagnost
method
studi
popul
found
high
preval
adenovirus
sampl
correspond
second
frequent
viru
detect
posit
sampl
frequenc
adenovirus
vari
differ
studi
depend
popul
select
screen
method
appli
diagnosi
studi
compar
sensit
differ
diagnost
method
demonstr
pcr
increas
number
posit
case
three
four
time
compar
immunofluoresc
assay
nevertheless
local
epidemiolog
characterist
overcrowd
poor
sanitari
condit
may
involv
consid
result
publish
moura
et
al
brazil
posit
sampl
children
hospit
lrti
adenoviru
screen
respiratori
virus
hospit
paulo
citi
year
use
immunofluoresc
assay
bezerra
pgm
et
al
also
report
similar
result
surveil
studi
carri
children
year
old
northeastern
region
brazil
collect
sampl
children
median
age
month
includ
hospit
outpati
rsv
frequent
pathogen
follow
adenoviru
hmpv
sever
analysi
reveal
children
rsv
like
hospit
infect
virus
syndrom
associ
wors
outcom
respiratori
viral
infect
compar
healthi
infant
populationbas
cohort
studi
demonstr
rate
hospit
children
ds
five
time
greater
longer
hospit
stay
gener
popul
even
absenc
concurr
risk
factor
respiratori
infect
consid
second
caus
death
children
ds
underus
alreadi
avail
access
prophylaxi
rsv
influenza
virus
studi
popul
sever
studi
demonstr
reduct
hospit
rate
mortal
highrisk
patient
receiv
passiv
prophylaxi
rsv
infect
last
five
year
extens
inclus
criteria
prophylax
brazil
major
chang
influenza
vaccin
given
children
year
age
rather
previou
year
age
limit
palivizumab
incorpor
nation
program
limit
minor
brazilian
state
chang
probabl
result
improv
respiratori
viru
surveil
system
throughout
countri
occur
respons
pandem
influenza
epidem
promot
awar
health
care
profession
popul
exist
prophylax
studi
alreadi
demonstr
increment
number
dose
influenza
vaccin
last
five
year
studi
limit
sampl
screen
respiratori
virus
known
caus
lower
respiratori
tract
infect
age
group
rhinoviru
enterovirus
coronavirus
human
bocaviru
probabl
explain
low
viru
detect
rate
respiratori
pathogen
caus
sever
respiratori
diseas
young
infant
bordetella
pertussi
also
includ
therefor
broader
diagnost
panel
includ
agent
might
provid
precis
analysi
howev
virus
includ
studi
wellestablish
caus
respiratori
infect
low
rate
viral
coinfect
except
adenovirus
low
rate
viral
persist
make
easier
compar
differ
etiolog
conclus
studi
found
young
age
underli
diseas
independ
risk
factor
wors
outcom
children
hospit
respiratori
viru
identif
special
popul
health
care
profession
along
fast
diagnosi
viral
natur
diseas
allow
aggress
approach
may
help
reduc
morbid
mortal
group
recent
chang
brazil
broader
access
avail
prevent
tool
direct
program
highrisk
popul
probabl
result
reduct
sever
respiratori
infect
children
futur
studi
evalu
new
scenario
necessari
confirm
posit
impact
prophylax
studi
approv
research
ethic
committe
santa
casa
de
rdia
hospit
univers
paulo
written
inform
consent
obtain
parent
guardian
child
enrol
studi
author
financi
compet
interest
giuliana
stravinska
durigon
edison
luiz
durigon
receiv
lectur
fee
abbott
brazil
eitan
naaman
berezin
receiv
lectur
fee
wyeth
pharmaceut
inc
